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ABSTRACT
Influence of Lactobacillus rhamnosus Isolated from “Amabere Amaruranu” Cultured Milk
on Adipogenesis
by
Justin Kotala
This study was performed to test the in vitro effects of a Lactobacillus rhamnosus isolate
from “amabere amaruranu”, a traditional Kenyan cultured milk, on 3T3-L1 and Caco-2
cell lines. Cultures of fully mature 3T3-L1 adipocytes were treated with bacterial isolate
cell extract (CE), filtered spent broth (FSB) from overnight bacterial culture, or with a
PBS control. Expression levels of PPAR³ 1 and 2, C/EBP±, and ATGL proteins in 3T3L1 cells were upregulated by FSB treatment. CE treatment did not affect protein
expression levels. Expression of MTTP and SREBP-1c proteins in Caco-2 cells showed
no change with either treatment. Optical density measurements from Oil-Red-O stained
3T3-L1 adipocytes increased from PBS control cells to 25µl/ml FSB treated cells;
measurements were reduced by treatments above 25µl/ml FSB. In conclusion, filtered
spent broth prepared from a culture of Lactobacillus rhamnosus, isolated from “amabere
amaruranu” cultured milk showed PPAR³ 1 and 2, C/EBP±, and ATGL agonistic
properties.
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CHAPTER 1
INTRODUCTION
Probiotic Definition
Prior to 2001, no one definition for the term probiotic was agreed upon. The
problem was clear that as the market for probiotics grew, the science behind probiotics
was lagging behind. In 2002, a joint Food and Agriculture Organization (FAO)/World
Health Organization (WHO) working group was assembled to draft effective guidelines
for the evaluation of probiotics in food. One of the main recommendations of this group
was to adopt the definition of a probiotic as “Live microorganisms that, when
administered in adequate amounts, confer a health benefit on the host” (Joint
FAO/WHO Working Group 2002). Other recommendations of this group were to adopt
guidelines put forth in the report for testing bacterial strains for probiotic qualities, follow
good manufacturing practices in the manufacturing of probiotic foods, as well as clear
labelling of probiotic foods including bacterial strains present and any health claims
(Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics
in Food 2002).
In 2008, Dr. Mary Ellen Sanders addressed the lack of oversight that still plagued
the growing industry. She acknowledged that even though the FDA is the regulatory
authority over probiotic products, it does not require a manufacturer of a probiotic
product to obtain premarket approval of any claims of efficacy or safety of that product
as long as the product is not marketed as a drug (Sanders 2008).

She concluded that

the improper use of the term probiotic within the industry could seriously undermine
consumer confidence, and that further controlled human studies are needed to validate
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health claims made by probiotic manufacturers (Sanders 2008). Her paper brought up
many of the same problems that the joint FAO/WHO working group tried to address
which could point towards the need for more oversight if the industry cannot regulate
itself.
In the past few years, the probiotic industry has experienced unprecedented
global market growth. According to a market report by BCC Research, formerly
Business Communications Company, published in December 2011, the global probiotic
market which includes sales of probiotic supplements, ingredients, and foods reached
approximately $21.6 Billion (US) in 2010 and was expected to have a compound annual
growth rate of 7.6% over the five year period (The probiotics market: Ingredients,
supplements, foods 2011). In 2013, a panel of experts from the International Scientific
Association for Probiotics and Prebiotics (ISAPP) was convened to revisit the definitions
and guidelines put forth 12 years earlier by the Joint Working Group and provide a
consensus statement for the appropriate scope and use of the term probiotic. This
convention was prompted by the market boom, widespread use of the term probiotic on
many products that did not meet minimum criteria, and scientific advances within the
field. Ultimately, the committee retained the FAO/WHO definition from 2001 and called
for more scientific evidence to be obtained before labelling a product probiotic (Hill et al.
2013).
Role of Probiotics in General Health
The probiotic industry has exploded over the last five to ten years with many
probiotic products on the market. The problem arises that science has not been able to
keep up with the pace of the market expansion and many of the product claims remain
11

scientifically unverified (Sanders 2008). With that being said, much work has been
done to elucidate the beneficial effects of probiotics on the body.
With the gut microbiome being implicated in many disease states, probiotics
have been increasingly studied because of their ability to change the microbial
community within the gut (Ji et al. 2012). The idea of modulating the microbiome from a
disease state to a healthy state to treat gastro-intestinal diseases that currently have
very limited treatments is enticing. Much of the early probiotic work was focused around
alleviating gastrointestinal (GI) diseases. Meta-analysis of clinical trials involving the
treatment of infectious diarrhea with rehydration therapy and probiotics showed that
probiotics significantly reduce the time period of diarrhea in patients treated with
probiotics (Allen et al. 2004). When treating symptoms of Irritable Bowel Syndrome with
probiotics, patients reported higher relief of symptoms than placebo group (Kajander et
al. 2008).
Studies done on the effectiveness of probiotics to treat food allergies and atopic
dermatitis have shown that probiotics do have an immuno-modulatory role. Many of
these studies have been focused around newborns since it is believed that the
maturation of the immune system is dependent on colonization of the newborn GI tract
by normal newborn microbiota. Differences in the microbiome were observed in
newborns delivered by vaginal delivery as opposed to Cesarean section (DominguezBello et al. 2010). Also, antibiotics prescribed to infants alters the microbiome and can
be linked with higher prevalence for immune mediated diseases such as Irritable Bowel
Disease (IBD), asthma, and obesity (Zeissig and Blumberg 2014). Infants with cow’s
milk allergy, treated with Lactobacillus GG, showed significant decrease in the incidence
12

of atopic dermatitis (Majamaa and Isolauri 1997). Lactic acid bacteria have been shown
to reduce cytokine production specific to allergic sensitivity, showing that probiotics can
have a direct impact on immune cells (Pochard et al. 2002). It would, therefore, seem
that probiotics can have a beneficial effect on the overall health of the host.
Lactobacillus rhamnosus Isolate
The potential probiotic used for this study was isolated from “amabere
amaruranu”, a traditional Kenyan cultured milk. This isolate was chosen for continued
testing because Lactobacillus species are generally considered safe for food and
supplementation (Joint FAO/WHO Working Group 2002). This isolate was shown to be
stable in digestive tract conditions, have no ability to degrade mucin, and was sensitive
to antibiotics.

The isolate was identified as L. rhamnosus by both 16s rRNA and

biochemical assay (Boyiri et al. 2014). These tests are recommended by the joint
FAO/WHO working group to establish a new bacterial isolate as a potential probiotic.
Human Gut Microbiome in General Health and Disease
The gastro-intestinal tract is home to a great diversity of microbiota. There are
approximately ten times more bacteria in the human gut than eukaryotic cells in the
human body. The compilation of this microbiota is still being discovered, but recent
studies have shown that the gastrointestinal tract is home to over 1200 distinct
microorganisms (Rajilic-Stojanovic et al. 2007). Although the exact bacterial
composition of the gut microbiome is unique to each individual, sequencing of the
human gut microbiome has shown that the majority of the organisms living in the GI
tract are members of either the Firmicute or Bacteroidetes phylum (Eckburg et al. 2005).
The proportions of these two phyla are stable in healthy populations but have been
13

shown to differ significantly in disease states such as obesity (Ley et al. 2006). This
diversity begins at birth. At birth, the neonatal intestine is sterile but immediately
colonized by bacteria from maternal and environmental sources, and progress to an
adult-like microbiome as the infant transitions to solid food (Palmer et al. 2007).
Ilya Metchnikoff was one of the first scientists to suggest that intestinal
microorganisms might play a role in human health by benefitting the host (O'Toole and
Cooney 2008). His ideas were mostly ignored until the 1990’s, when research into the
gut microbiome and its role in human health gained acceptance. The human gut
microbiome has become a topic of focus for research since very little was known about
it until recently. New high throughput sequencing techniques have allowed researchers
to develop new insight into the composition and functionality of the microbiome. As the
relationship between the gut microbiome and its human host is better analyzed,
researchers are coming to realize that the gut microbiome has more effects than just in
aiding digestion.
Gut Microbiome in Gastrointestinal Health
The gut microbiome could be looked at as another organ. In healthy individuals,
the microbiome works symbiotically with the host to help facilitate digestion and uptake
of nutrients from food. One important function to humans is that it allows for the
processing and digestion of foods that would be otherwise indigestible, like plant
polysaccharides (Bergman 1990; Samuel and Gordon 2006) and gluten (Caminero et
al. 2014). Mutualism exists within the microbiome as organisms function to catabolize
nutrients in the GI tract, which support a healthy diverse microbiome (Samuel and
Gordon 2006). This mutualistic role that the gut microbiome plays has allowed for the
14

digestion and metabolism of foods without humans needing to evolve the ability to
produce specific enzymes for this task. It has been determined for some time that long
term lifestyle habits alter the make-up of the gastro-intestinal microorganisms, but now
research shows that short term shifts in diet can alter the gut microbiome within days of
such a shift (David et al. 2014). This same study showed a correlation between diet
composition, be it plant based or animal based, and changes in bacterial diversity in the
GI tract.
Being that the gut microbiome is integral for proper digestion, it should come as
no surprise that altered gut microbiomes have been associated with gastrointestinal
disorders. Studies done with Celiac Disease (CD) patients show that they have
elevated levels of both Bacteroides and Clostridium leptum, along with decreased levels
of Bifidobacterium as compared to healthy control groups (Collado et al. 2009). Another
study showed that microbial diversity of fecal samples from untreated CD patients
cluster together, while fecal samples from CD patients treated with a gluten free diet for
at least two years show a microbial diversity that reflects that of healthy control subjects
(Nistal et al. 2012). These studies point to dysbiosis within the gut microbiota. It is not
clear, however, if these changes in the microbiome are caused by the diseases or
cause the disease state, and more studies are needed to link specific microbial
signatures to specific diseases (De Palma et al. 2014).
Gut Microbiome in Immunity and Gut-Brain Axis
The gut microbiome plays an important role in the development of a mature
immune system. Infants born by Caesarian section are at a higher risk of developing
allergies and asthma (Bager et al. 2008). Such studies reinforce the idea that
15

mutualism exists between the gut microbiome and the host immune system (Maynard et
al. 2012). A recent study suggests that Clostridia, present in normal gut microbiome,
may play a role in helping to reduce food allergen sensitization through an immuneregulatory role (Stefka et al. 2014). This could prove useful in finding a way to prevent
food allergies or desensitize patients with existing food allergies.
It has been known for some time that there is a bidirectional flow of information
between the brain and the gut. This has been termed the gut-brain axis. The gut
microbiome has been shown to play a role in the communication between the brain and
gut. This relationship was made apparent with studies of patients with hepatic
encephalopathy. Hepatic encephalopathy patients showed signs of improvement after
administration of antibiotics as well as probiotics (Victor and Quigley 2014). More
evidence of a brain-gut microbiome link came from studies showing differences in the
composition of the gut microbiome of autistic and control siblings (Finegold et al. 2010).
Additionally, autistic patients reported improved symptoms with antibiotic use (Finegold
2011). Stress and gut microbiota dysbiosis has been reported as well. Stress
introduced into an animal model was shown to induce changes within the diversity of
the microbiome as well as innate immune response (Bailey et al. 2011). The innate
immune response was not seen when the same experiment was performed with mice
that had received an antibiotic treatment that reduced the gut microbiota. This suggests
that the gut microbiome plays a role in innate immune responses to stress.
Human Gut Microbiota in Obesity and Type 2 Diabetes
As obesity continues to be a major health concern around the world, researchers
look for ways to therapeutically target the disease. In the search for a solution to the
16

obesity epidemic, attention has been paid to the gut microbiota and its involvement in
obesity. The intestinal microbiota plays a major role in digestion and energy harvest as
shown through the study of germ free and conventionally raised mice (Backhed et al.
2004). Germ free mice have significantly lower total body fat than their wild type
counterparts, even though the germ free mice were consuming more chow than the wild
type mice. Also, the same study showed that the gut microbiota was able to regulate
gene expression linked to energy harvest. The link between obesity and gut microbiota
was revealed when metagenomic sequencing of obese and lean mice showed a
difference in the makeup of the microbiome. Obese mice had a higher proportion of
bacteria of the division Firmicutes, and less of the division Bacteroidetes than lean mice
(Ley et al. 2005). This proportional difference of the gut microbiome was also observed
in obese and lean humans (Ley et al. 2006).
To further tease out the contributing factors of obesity, metagenomic and
biochemical aspects of the obese and lean mouse distal gut microbiome have been
examined. The obese microbiome was found to be more capable of harvesting energy
from the mouse’s diet (Turnbaugh et al. 2006). This same study showed that this
increased energy harvest ability was transmissible from obese mice to germ free mice
by inoculating the germ free mice with the obese microbiota. Although this does not
prove causality, it shows that the gut microbiome plays a major role in energy harvest
and obesity.
Gastric bypass surgery has been an effective surgical option for severely obese
individuals to rapidly lose weight. Recently, it was proposed that gastric bypass surgery
works to reduce weight and improve glucose tolerance through a shift in the gut
17

microbiome instead of reducing weight by calorie restriction alone. In sequencing the
gut microbiome of patients and mouse models of gastric bypass surgery, a shift in the
microbiota that altered the energy balance in the host was shown (Liou et al. 2013).
This study also showed that by transplanting the gut microbiota from mice that had just
had gastric bypass into germ free obese mice, they were able to induce weight loss in
the germ free mice.
As the main focus of this study is being put on obesity, it is important to note that
another very serious and related problem is Type 2 Diabetes (T2D). T2D is associated
with insulin resistance. Although there is no clear causality between obesity and T2D,
obesity can increase the risk of acquiring insulin resistance and subsequent T2D
through low grade chronic inflammation (Das and Mukhopadhyay 2011).
Endocannabinoid System in Obesity and Insulin Resistance
A major question that arises when looking at a correlation between the gut
microbiome and obesity is how does the microbiome interact with the host systems in
the presence of the mucosal barrier? The answer may be in the endocannabinoid
system (ECS). The ECS consists of bioactive lipids that are important in controlling
many physiological functions. Evidence for a link between the ECS and obesity has
been shown by knocking out the expression of the bioactive lipid synthesis gene in
mouse adipocytes, and thereby show that the ECS is responsible for energy
homeostasis throughout the body (Geurts et al. 2015). The knockout mice had greater
total fat mass, body-weight gain and a higher insulin resistance index while maintaining
the same food intake as control mice. This same study reinforced the idea of an
association between adiposity, the ECS and gut microbiome when researchers found
18

significant changes in the gut microbiota of knockout mice. While a shift in gut
microbiome was associated with this genetic knockout, long-term antibiotic treatment
improved body-weight gain, fat mass, and reduced insulin resistance index in knockout
mice. Researchers were able to partially replicate the knockout phenotype by
transferring the gut microbiome from knockout mice into wild type germ free mice. This
study strengthens the argument for a correlation between the gut microbiome, ECS and
obesity.
Probiotics and Their Influence on Adipogenesis
The gut microbiome controls many more aspects of the host body than had ever
been imagined. Since there are correlations between disease states and shifts in host
gut microbiome, then disease states should be improved by manipulating the gut
microbiome into a more normal state. Research to support this hypothesis showed that
a lean gut microbiome transferred to an obese mouse will incur significant weight loss
(Ridaura et al. 2013). Hence a manipulation of the gut microbiome is a viable method to
fight diseases that contribute to a disease shifted microbiome. Probiotics can
manipulate the gut microbiome and regulate various host systems to improve many
aspects of a disease.
A number of probiotic strains have been shown to affect adipogenesis in cell
culture. A probiotic isolated from Kimchi, a traditional fermented dish, has inhibitory
effects on intracellular lipid accumulation in vitro (Moon et al. 2012). This study treated
3T3-L1 cell culture with either spent media or cytoplasmic fraction from the culturing of
the isolated probiotic, Weissella koreensis, a lactic acid bacteria. They were able to
show that the probiotic treatment lowered both lipid accumulation inside of the cells, as
19

well as mRNA expression levels of key adipogenic transcription factors. Another
probiotic isolated from kimchi called Lactobacillus plantarum KY1032 was also shown to
maintain probiotic activity and regulate lipid metabolism by testing the cytoplasmic
fraction in 3T3-L1 cells (Park et al. 2011). This probiotic significantly downregulated
adipogenic transcription factors and also lowered lipid content within the adipose cells.
Cell culture studies are a great way to show proof of concept, but it is important
to understand how probiotics interact with host systems. Mouse models work as good
indicators of how a certain probiotic will interact with a human host. Different species
and strains of lactic acid bacteria have been used to elucidate anti-obesity effects. L.
gasseri BNR17 was one such bacteria that was shown to reduce levels of leptin and
insulin while increasing expression of fatty acid metabolism related genes (Kang et al.
2013). A similar study used L. rhamnosus PL60 to incur weight loss and reduce white
adipose tissue deposits in diet induced obese mice (Lee et al. 2006).
All of these studies have looked at modelling the human obesity condition, but
even the best models will differ from human physiology. Therefore it is important to also
look at human trials to show that probiotics can carry over the anti-obesity effects shown
in models to human hosts. In a human trial using adults with obese tendencies, L.
gasseri SBT2055 was shown to significantly reduce abdominal adiposity as well as
other markers of obesity (Kadooka et al. 2010). Another study tested the effects of L.
acidophilus NCFM to improve insulin sensitivity in male subjects with Type 2 Diabetes.
The study showed that the probiotic was able to preserve insulin sensitivity compared
with a control group (Andreasen et al. 2010). Human trials continue to provide insight
into new treatments for obesity and Type 2 Diabetes.
20

Probiotic research has improved the collective knowledge of both the human
body systems as well as how bacteria interact with these systems. This research has
shown that many beneficial effects of probiotics are strain specific. These studies have
created a precedent for effectively testing novel probiotics and their efficacy in
regulating adipogenesis.
Adipogenic Transcription Factors
When studying effects of a compound on a biological system, it is important to
understand how the compound elicits the effect that it has. To do so, the system can be
studied at the molecular level to see how the compound affects the protein and gene
expression levels that drive the biological system. In this case, adipogenesis is a
complex interplay between many different genes that regulate each other as illustrated
in Figure 1. The present study will focus on four primary transcription factors that have
been shown to be critical to the maturation of adipose cells and the storage of lipids:
PPAR³ , C/EBP±, SREBP-1c, and ATGL.
In order to study the effect of a novel probiotic on the adipogenic pathway, cell
culture modelling is the most efficient way to begin. The 3T3-L1 cell line was chosen for
use in this study. The 3T3-L1 cell line is an adipocyte lineage that was first established
in 1975. This cell line has been used extensively to study the mechanisms of
adipogenesis because of its similarity to human adipocytes. Once exposed to a nutrient
cocktail which includes isobutylmethylxanthine (IBMX), dexamethasone and insulin, the
preadipocytes will differentiate into mature adipocytes. This maturation process
expresses multiple metabolic programs that are characteristic of mature fat cells. The
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validity of this cell line as a model of adipocyte formation is supported by many studies
performed in both mouse and human tissue (Farmer 2006).
PPAR-³
PPAR³ is considered the master regulator of adipogenesis. Originally thought to
work co-dependently with C/EBP±, it was shown that PPAR³ alone can induce
adipogenesis. This was elucidated by doing both gain of function, and loss of function
studies on PPAR³ . Gain of function studies showed that ectopic expression of PPAR³ 2
in multiple fibroblast cell lines caused them to differentiate into adipocytes (Tontonoz et
al. 1994b). The loss of function study was done by Rosen and collegues, and involved
using embryonic stem (ES) cells that lacked a normal PPAR³ gene. These cells were
not able to differentiate into adipose cells in vitro (Rosen et al. 1999). Rosen’s study
also used a chimeric mouse model to show that mice not expressing PPAR³ could not
produce adipose tissue.
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Figure 1. A pathway map of adipogenesis. Key points from this map are that PPAR³ 2
is the bottleneck point for the differentiation process. SREBP-1c is directly influenced
by insulin. C/EBP± forms a positive feedback loop with PPAR³ 2 to maintain expression
in mature adipocytes. The four transcription factors focused on in this project are
outlined in bold.
PPAR³ is expressed in adipose cells as two isoforms, PPAR³ 1 and PPAR³ 2.
Both isoforms are exactly the same except that the PPAR³ 2 isoform contains an
additional 30 amino acids at the amino terminus (Tontonoz et al. 1994a). Tontonoz and
colleagues showed that while PPAR³ 1 is expressed in several different types of tissue,
PPAR³ 2 is specific to adipocytes. PPAR³ 2 was shown to be the critical transcription
factor that regulated cellular differentiation and lipid storage during adipogenesis (Ren
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et al. 2002). Ren and colleagues developed a knockout study that showed clearly that
PPAR³ 1 expression without PPAR³ 2 expression could not trigger adipogenesis in 3T3L1 cells, therefore showing conclusively that PPAR³ 2 is crucial for adipogenesis.
PPAR³ is the target for a class of antidiabetic drugs called thiazolidinediones.
How this class of drugs worked was unclear until Lehmann and colleagues showed that
Thiazolidinediones are direct agonists for PPAR³ (Lehmann et al. 1995). This class of
drugs, which includes Rosiglitazone, is used to treat Type 2 Diabetes. Although these
drugs are effective at controlling blood glucose levels in patients with Type 2 Diabetes,
they are known for having many side effects. Other effective methods for treating Type
2 Diabetes with less side effects are needed.
C/EBP±
CCAAT/Enhancer-binding Protein ± is another critical transcriptional regulator of
adipogenesis. Once assumed to be equal to PPAR³ in its role as a master regulator, it
was shown to not be as important as PPAR³ in regulating the entire pathway. With that
being said, C/EBP± has been shown to be critical in conveying insulin sensitivity to the
mature adipocyte. Wu and colleagues were able to show that PPAR³ activates
expression of C/EBP±, which then enters a positive feedback loop with PPAR³ ensuring
terminal differentiation and high-level expression of both genes in differentiated cells
(Wu et al. 1999). The differentiation pathway for creating mature adipocytes is not fully
understood. What is now known is that as C/EBP² is needed to bind to the C/EBP±
promoter site, but cannot induce transcription without the presence of PPAR³ (Zuo et al.
2006).
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In addition to positively regulating PPAR³ , C/EBP± is critically important in
conferring insulin sensitivity to the mature adipocyte. During C/EBP± knockout studies,
it was observed that the mature adipocytes had no insulin-stimulated glucose transport
(Wu et al. 1999). C/EBP± is responsible for the expression of many insulin sensitivity
factors such as GLUT4, as well as fatty acid transporter, FAT/CD36 (Qiao et al. 2008).
ATGL
Adipose Triglyceride Lipase (ATGL) was first identified in 2004 by three
independent research groups. It is expressed predominantly in both white and brown
adipose tissue and localizes on the lipid droplets (Zechner et al. 2005). This enzyme
has high substrate specificity for triacylglycerol (TG) and is responsible for the first step
in lipolysis, hydrolyzing TG into Diacylglycerol (DG) and fatty acid (FA) (Zimmermann et
al. 2004). Before this discovery, the enzymes hormone-sensitive lipase (HSL) and
monoglyceride lipase (MGL) were thought to be the main enzymes that drive lipolysis.
MGL performs the last step in the pathway of hydrolyzing monoglycerides into glycerol
and FA. HSL was known to have broad substrate specificity to lipid esters. HSL
knockout studies had shown that there were other enzymes involved in the pathway
though. ATGL completed the pathway becoming the rate limiting enzyme for the
process of TG mobilization (Chakrabarti and Kandror 2011).
ATGL levels vary during feeding and fasting. Both the mRNA and protein
concentrations are affected by nutritional status. ATGL activity has been shown to be
regulated through both gene expression and post-translational modification (Chakrabarti
and Kandror 2011). The ATGL transcript was shown to be downregulated by insulin
during refeeding periods, as well as downregulated due to treatment with TNF-± and is
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a direct transcriptional target of PPAR³ (Kim et al. 2006). Apart from being regulated at
the transcriptional level, ATGL is also regulated post-transcriptionally by the lipid protein
Comparative Gene Identification 58 (CGI-58). CGI-58 binds to the lipid droplet by
interacting with perilipin A when the cell is not stimulated. Once the adipocytes are
stimulated, the CGI-58 dissassociates from the lipid surface and perilipin A to enter the
cytosol where it interacts with ATGL protein to activate lipolysis (Zechner et al. 2009).
ATGL knockout studies showed that there was a significant reduction of FA
released from adipose tissue and increased fat accumulation throughout all tissue in the
knockout animal (Zechner et al. 2009). This was contrary to what was seen during
HSL-knockout studies which showed a decreased fat mass in those animals. This
indicates that ATGL is critical for maintaining FA levels within the body. Also contrary is
that total cholesterol and HDL cholesterol concentrations are reduced in ATGL
knockouts but raised in HSL knockouts. Human cases of ATGL deficiency have been
reported. These cases arise from a mutation within the ATGL gene that leads to the
expression of a truncated, but still enzymatically active, protein. Like ATGL knockout
mice, these patients present with systemic tryglyceride accumulation along with cardiac
myopathy but do not develop insulin resistance (Lass et al. 2011).
SREBP-1c
Sterol Regulatory Binding Protein-1c is a transcription factor that is primarily
expressed in the liver, white adipose tissue, adrenal gland and brain (Shimomura et al.
1997). It is primarily responsible for expression of lipogenic genes. Genetic knockout
studies showed that SREBP-1c regulates the expression of the lipogenic genes such as
glucose-6-phosphate dehydrogenase and glycerol-3-phosphate acyltransferase as well
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as cholesterol enzyme Fatty Acid Synthase (Liang et al. 2002). This makes SREBP-1c
a key player in cholesterol and fatty acid metabolism, both important to patients with
T2D. In obesity and T2D, glucose and free fatty acids are not stored properly in
adipose tissue, allowing them to continue in high levels in the blood and store in other
tissues.
The balance of metabolic energy is a complex, closely regulated balance
between a fasting and fed state. Adipose tissue is the main site for excess energy
storage, where in energy excess, triglycerides are built and stored. During energy
depletion, these energy stores are broken down into free fatty acids and released into
the bloodstream. The switch between fasting and fed state is primarily controlled by
insulin levels, which is released in response to blood glucose levels. An increased
insulin level signals a fed state whereas a low insulin level is indicative of a fasting state.
Insulin was shown to be a direct agonist for SREBP-1c (Azzout-Marniche et al. 2000).
The introduction of insulin into cultured cells caused the rapid synthesis of SREBP-1c
thereby triggering increased expression of other lipogenic genes needed for energy
storage.
Lipid Absorption and Transport by Intestinal Epithelial Cells
The gastrointestinal lumen is the gateway through which dietary fats are
absorbed and a physical barrier to the gut microbiome. Because of the importance of
the gastrointestinal lumen in nutrient and drug absorption, it is the target of many
studies. Due to the fact that lipids are transported through the lymphatic system
whereas water soluble compounds are transported through the hepatic system, lipid
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transport is an enticing option to increase drug bioavailability by avoiding the first pass
effect of the hepatic system (Nauli and Nauli 2013).
Lipids are first absorbed by enterocytes in the gut lumen as part of the nutrient
absorption process. The enterocytes then package the lipids into chylomicrons and
secrete them into the lymphatic system where they are hydrolyzed and absorbed by
other tissues. For this packaging and transport to occur, a well-controlled pathway is
triggered to transport the lipids to the Endoplasmic reticulum of the luminal cell where
Microsomal Triglyceride transfer protein forms a chylomicron. Figure 2 illustrates the
pathway for fatty acid absorption into the luminal cell and chylomicron synthesis in the
Endoplasmic Reticulum. Chylomicrons are transported through the cell and exocytosed
into the lamina propria and into the lymphatic system. They travel through the lymphatic
system eventually entering the bloodstream and are broken down into components by
endothelial cells (Dash et al. 2015).
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Figure 2: The pathway for fatty acid absorption and chylomicron production is a
complex, closely regulated process. Fatty acids and cholesterol are absorbed through
the brush border and transported to the ER where MTTP begins the process of
synthesizing a chylomicron. The chylomicron is transported to the golgi where it
matures and is exported to the lymphatic system. Image from (Pan and Hussain 2012).
Biochim. Biophys.Acta 1821:727–35 (116)
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The gastrointestinal tract has been the target of many studies to understand
nutrient absorption and its role in obesity. An effective way to lower plasma triglyceride
levels would be to reduce the uptake of them from the gastrointestinal lumen. One
such study showed that polyphenol-rich black chokeberry extract has the ability to
regulate gene expression, notably reducing SREBP-1c and other lipid metabolism
genes in a dose dependent manner in enterocytes (Kim et al. 2013). This study
indicates that lipid metabolism and chylomicron production could be altered by a natural
extract. Another study was able to show that short chain fatty acids reduced the export
of lipids and cholesterol out of the small intestine by reducing the expression of
microsomal triglyceride transfer protein (MTTP) (Marcil et al. 2003). Even though it is
not clear whether the probiotic extract being studied possesses hypolipidemic qualities,
the presence of reduced expression of genes linked to lipid metabolism and
chylomicron production would strengthen the argument that probiotics could be an
effective alternative treatment for obesity and Type 2 Diabetes
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CHAPTER 2
MATERIALS AND METHODS
Isolation of L. rhamnosus and preparation of filtered Spent Broth (FSB) and Cell Extract
(CE)
L. rhamnosus was previously isolated and identified, using both 16S rRNA
sequencing and biochemical testing, from “amabere amaruranu” a Kenyan cultured milk
source (Boyiri et al. 2014). The L. rhamnosus isolate was cultured in deMan-RogosaSharpe (MRS) broth and incubated at 37⁰C for 24 hours until they reached an optical
density of 2.0 at 550nm or approximately 1.0x109 cfu/ml. At that time the bacterial broth
culture was centrifuged at 1100g for 15 minutes at 4⁰C to separate spent broth from live
bacteria.
The supernatant was decanted to collect the spent broth. At this point, the spent
broth was at a low pH due to the growth of lactic acid bacteria. The spent broth was
raised to a pH of 7.4 using NaOH and filtered using a 0.22µm filter. FSB was then used
to treat the differentiating adipocytes.
The bacterial pellet was resuspended in 50ml of PBS. The bacterial suspension
was sonicated 5 times at 44% amplitude for 2 minutes with 6 minutes of rest. The
sonicate was then centrifuged at 1100g for 15 minutes at 4⁰C. The supernatant was
collected, filtered through a 0.22µm filter, and labelled CE. The CE was used to treat
the differentiating adipocytes.
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To test for the presence of heat-labile proteins, FSB was heated to produce heat
inactivated broth (HIB). To do this, FSB was heated in a water bath at 95⁰C for 10
minutes.
Growth of 3T3-L1A Adipocyte Cells
To test the effects of the probiotic on adipogenesis, the bacteria and bacterial
extracellular products were tested on an adipocyte 3T3-L1A cell line. The fibroblastic
preadipocytes were grown to confluence in Dulbecco’s Modified Eagles Medium
(DMEM) containing high glucose supplemented with 10% Fetal Bovine Serum (FBS)
and 100µg/ml Penicillin/Streptomycin at 37⁰C and 5%CO 2 . Two days after the cells
reached full confluence, a differentiation cocktail of 1µg/ml Insulin, 1µM
Dexamethasone, 0.5mM 3-isobutyl-1-methylxanthine (IBMX), and 2µM Rosiglitazone
was introduced to the cell growth medium. The cells were incubated for 48 hours in this
differentiation medium. After that time, the medium was changed to growth medium
containing only 1µg/ml insulin and allowed to incubate 48 hours. After 48 hours in
growth medium containing insulin, the cells were incubated for the remainder of the time
in fresh growth medium. Media was changed every 48 hours until harvest on day 10.
The cells were harvested using a cell scraper 10 days after differentiation and
were lysed using RadioImmuno-Precipitation assay (RIPA) buffer. The cell lysate was
sonicated and centrifuged at 12,000 rpm for 20 minutes to separate any unwanted cell
fragments from the proteins. The proteins were then collected as the lysate supernatant
and stored at -80

p Cfuture assays.
for
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Treatment of Differentiating Adipocytes
To test the dose dependent effects of the probiotic treatment, differentiating
adipocytes were treated with different concentrations of FSB or CE (10, 25, 50, 75, or
100µl/ml of media) added to the growth media. The treatment was started at
differentiation day 0 and continued for 10 days. New treatment was added at every
media change. PBS was used as a negative control.
Growth of Caco-2 Cells
Caco-2 cells were grown in DMEM containing high glucose media supplemented
with 10% FBS and 100µg/ml Pen/Strep until reaching confluence at 37⁰C and 5% CO 2 .
Once confluent, the cell culture was allowed to continue growth until 14 days after
confluence in which the cells had spontaneously differentiated to resemble the lining of
the small intestine. At this time the cells were treated with different concentrations of
FSB, CE, or PBS control for 24 hours and then harvested using a cell scraper and lysed
using RIPA buffer. The cell lysate was sonicated and centrifuged at 12,000 rpm for 20
minutes to separate any unwanted cell fragments from the proteins. The proteins were
then collected as the lysate supernatant and stored at -80

p Cfuture assays.
for

Quantification of Lipid Present in Adipocytes by Oil-Red-O Staining
Intracellular lipid accumulation was measured using Oil-Red-O staining. The
3T3-L1A cells were cultured as described above. At the time of differentiation, they
were treated with differing concentrations of FSB or PBS as a control. After 10 days the
cell plates were collected, growth medium removed and 10% formaldehyde added to
the wells for 5 minutes. After 5 minutes, the old formaldehyde was removed and fresh
formaldehyde added and allowed to sit for at least 1 hour. After this the formaldehyde
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was removed and wells washed with 60% isopropanol and allowed to dry completely.
At this point, Oil-Red-O working solution was added to the wells and left to sit for 10
minutes. The Oil-Red-O was removed and distilled H2O was immediately added to the
wells. The wells were washed with water until no more red flakes were observed in the
waste water and left to dry. At this point the cells were observed under microscopy for
appearance of stained lipid droplets in the cells.
To quantify the lipid content in the wells, the Oil-Red-O was eluted by adding
100% isopropanol to the wells and letting it sit for 10 minutes. The isopropanol was
then pipetted several times to remove all stain from the wells and transferred to a
spectrophotometric cuvette. The stained isopropanol was measured by
spectrophotometry for optical density at 500nm.
Western Blot Analysis
3T3-L1A cells were treated with differing concentrations of FSB, CE, or PBS
control at time of differentiation and then continuously for 10 days. After 10 days they
were harvested and lysed using RIPA buffer and protein content measured using
bicinchoninic acid assay (BCA). To ensure uniform concentrations, all samples were
diluted down to a protein concentration of 2.0 mg/ml as measured by BCA. Protein was
separated by running through 10% SDS-PAGE gel and transferred to PVDF
membranes. The membranes were blocked using 5% nonfat milk in Tris-Buffered
Saline with Tween-20. They were then incubated with various antibodies against
PPAR³ , C/EBP±, ATGL, and SREBP-1c (Cell Signaling). Chemiluminescense was
developed using the SuperSignal West Femto chemiluminescense kit (Thermo).
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Analysis of the effects of FSB on Caco-2 cells was performed by measuring
expression of Fatty Acid Synthase (FAS), Microsomal Triglyceride Transfer Protein
(MTP), and SREBP-1c. Western blots were run as described above, and incubated
against antibodies to these proteins.
Alphaview software was used to quantify all Western blot images. All data was
reported in relative intensity compared to control bands.
Statistical Analysis
Statistical Analysis Systems (SAS) software was used to analyze quantitative
data. One way ANOVA was run on the quantified western blot data. Individual data
points were compiled and represented as Least Square means.
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CHAPTER 3
RESULTS
Effects of Probiotic Treatment on 3T3-L1A Cells
To measure the effect of various levels of the probiotic treatment, Western Blot
analysis was performed on various transcription factors that are important in regulating
adipogenesis and lipid storage in adipocytes. 3T3-L1A cells were treated with either
Filtered Spent Broth or Cell Extract of L. rhamnosus cultures in varying doses (0, 10, 25,
50, 75, or 100µl/ml) at differentiation and the protein concentration was measured. The
values for the Western Blot were quantified by measuring the band intensity relative to
the control band. Therefore all values are presented as fold changes compared to the
control band.
PPAR³ 1
PPAR³ 1 protein expression levels were increased in response to treatment with
FSB roughly in a dose dependent manner. Expression levels showed 1.2 to 3.1 fold
increase when compared to control levels as shown in Table 1. Table 2 shows the
mean expression levels of PPAR³ 1 when treated with CE. As both Table 2 and Figure
4 show, there was no change in the expression levels of PPAR³ 1 or PPAR³ 2 after
treatment with CE. The upregulation of protein expression following FSB treatment was
a contrast to the no expression change when CE treatment was applied. The Western
Blot shows that FSB treatment does induce increased expression of PPAR³ 1, while CE
treatment had no effect.
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Figure 3: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of PPAR³ 1 in 3T3-L1A adipocytes. Figure 3a is the
western blot image. Figure 3b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of 0
µl/ml. Each bar represents mean fold change values. The Y-axis has been set to 1 to
normalize the graph to the control.
Table 1: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of PPAR³ 1 in 3T3-L1A adipocytes
Relative expressiona

FSB concentration (µl/ml media)
0µl/ml

1

10µl/ml

1.235

25µl/ml

1.449

50µl/ml

2.276

75µl/ml

3.094

100µl/ml
2.452
a
Protein expression values are of mean fold change. n=3 to 7. Mean fold changes
are of protein expression relative to the positive control.
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Figure 4a
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Figure 4: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on
the protein expression of PPAR³ 1 in 3T3-L1A adipocytes. Figure 4a is the western blot
image. Figure 4b represents the quantification of the protein expression. Expression is
presented as fold change relative to the control CE concentration of 0µl/ml. Each bar
represents mean fold change. The Y-axis has been set to 1 to normalize the graph to
the control.
Table 2: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on
the protein expression of PPAR³ 1 in 3T3-L1A adipocytes
Relative expressiona

CE concentration (µl/ml media)

a

0µl/ml

1

10µl/ml

1.14

25µl/ml

0.958

50µl/ml

0.907

75µl/ml

1.144

100µl/ml
0.925
Expression values are mean fold change. n = 1 to 3. Mean fold changes are of

protein expression relative to the positive control.
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PPAR³ 2
PPAR³ 2 expression levels show a 1.2 to 3.0 fold increase in response to
treatment with FSB (Table 3 and Figure 5). Table 3 shows that the mean values of the
protein expression were almost identical to PPAR³ 1 levels. Table 4 and Figure 6 show
that CE did not affect PPAR³ 2 expression levels as evident by no change in mean
treated values from control. Like PPAR³ 1, ³ 2 expression was upregulated by the FSB
but not CE which indicates that a component present in the FSB can interact with
differentiating adipocytes to increase PPAR³ protein expression.
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Figure 5: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes. Figure 5a is the
western blot image. Figure 5b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of
0µl/ml. Each bar represents mean fold changes. The Y-axis has been set to 1 to
normalize the graph to the control.
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Table 3: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes
Relative expressiona

FSB Concentration (µl/ml media)
0µl/ml

1

10µl/ml

1.181

25µl/ml

1.545

50µl/ml

2.276

75µl/ml

3.013

100µl/ml

2.461

a

Expression values are mean fold change. n = 3 to 7. Mean fold changes are of protein

expression relative to the positive control.
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Figure 6: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture
on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes. Figure 6a is the western
blot image. Figure 6b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control CE concentration of 0
µl/ml. Each bar represents mean fold changes. The Y-axis has been set to 1 to
normalize the graph to the control.
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Table 4: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on
the protein expression of PPAR³ 2 in 3T3-L1A adipocytes
Relative expressiona

CE concentration (µl/ml media)
0µl/ml

1

10µl/ml

1.058

25µl/ml

0.89

50µl/ml

0.874

75µl/ml

1.082

100µl/ml
0.839
a
Expression values are mean fold changes. n = 1 to 3. Mean fold changes are of
protein expression relative to the positive control.

C/EBP±
C/EBP± is downstream of PPAR³ and is responsible for many aspects of insulin
sensitivity within the adipocyte. The Western Blot data revealed that the FSB treatment
did impart some upregulation of this protein expression but not to the extent of the
PPAR³ expression. Protein expression was recorded at a 1.3 to 1.9 fold increase due
to FSB treatment (Table 5, Figure 7). There was a slight increase in expression with
higher doses of CE treatment, specifically a 1.3 fold increase at 100 µl/ml CE treatment
(Table 6, Figure 8).
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Figure 7: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of C/EBP± in 3T3-L1A adipocytes. Figure 7a is the
western blot image. Figure 7b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of 0
µl/ml. Each bar represents mean fold change. The Y-axis has been set to 1 to
normalize the graph to the control.
Table 5: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the protein expression of C/EBP± in 3T3-L1A adipocytes
Relative expressiona

FSB concentration (µl/ml media)
0µl/ml

1

10µl/ml

0.949

25µl/ml

1.321

50µl/ml

1.674

75µl/ml

1.757

100µl/ml

1.866

a

Expression values are mean fold changes. n = 1 to 6. Mean fold changes are of protein

expression relative to positive control.
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Figure 8: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture
on the protein expression of C/EBP± in 3T3-L1A adipocytes. Figure 8a is the western
blot image. Figure 8b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control CE concentration of 0
µl/ml. Each bar represents mean fold changes. The Y-axis has been set to 1 to
normalize the graph to the control.
Table 6: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on
the protein expression of C/EBP± in 3T3-L1A adipocytes

a

CE concentration (µl/ml media)

Relative expressiona

0µl/ml

1

10µl/ml

1.09

25µl/ml

1.065

50µl/ml

1.046

75µl/ml

1.291

100µl/ml

1.344

Expression values are mean fold changes. n = 1 to 2. Mean fold changes are of protein

expression relative to the positive control.
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ATGL
Western Blot analysis revealed that ATGL had the highest increase in protein
expression due to FSB, with fold increases ranging from 1.2 to 3.2 times greater than
control (Table 7, Figure 9). In contrast, ATGL also showed the lowest decrease in
protein expression due to treatment with CE, with expression levels as much as 2 times
lower than control values (Table 8, Figure 10). CE treatment was only able to decrease
ATGL expression levels.
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Figure 9: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the expression of ATGL in 3T3-L1A adipocytes. Figure 9a is the western blot
image. Figure 9b represents the quantification of the protein expression. Expression is
presented as fold change relative to the control FSB concentration of 0 µl/ml. Each bar
represents mean fold changes. The Y-axis has been set to 1 to normalize the graph to
the control.

44

Table 7: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the expression of ATGL in 3T3-L1A adipocytes
Relative expressiona

FSB concentration (µl/ml media)
0µl/ml

1

10µl/ml

0.928

25µl/ml

1.151

50µl/ml

2.214

75µl/ml

3.234

100µl/ml

2.516

a

Expression values are mean fold changes. n = 3 to 8. Mean fold changes are of protein

expression relative to the positive control.
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Figure 10: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture
on the expression of ATGL in 3T3-L1A adipocytes. Figure 10a is the western blot
image. Figure 10b represents the quantification of the protein expression. Expression
is presented as fold change relative to the control CE concentration of 0 µl/ml. Each bar
represents mean fold changes. The Y-axis has been set to 1 to normalize the graph to
the control.
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Table 8: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on
the expression of ATGL in 3T3-L1A adipocytes

a

CE concentration (µl/ml media)

Relative expressiona

0µl/ml

1

10µl/ml

0.957

25µl/ml

0.872

50µl/ml

0.585

75µl/ml

0.709

100µl/ml

0.598

Expression values are mean fold changes. n = 1 to 5. Mean fold changes are of protein

expression relative to the positive control.

SREBP-1c
SREBP-1c expression levels were increased by FSB treatments to 1.2 to 1.4
times higher than seen with control treatment (Table 9, Figure 11). Unlike other protein
expression levels which showed a dose response curve when plotted, SREBP-1c
expression data after FSB treatments created a bell curve when plotted, with the
highest expression level coming from 50 µl/ml of FSB treatment. CE treatment
increased SREBP-1c expression levels 1.2 to 1.3 times control levels (Table 10, Figure
12). Dose response seemed to be absent with this treatment as all of the different
doses except 50 µl/ml increased expression to roughly the same level.
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Figure 11a
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Figure 11: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the expression of SREBP-1c in 3T3-L1A adipocytes. Figure 11a is the
western blot image. Figure 11b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of 0
µl/ml. Each bar represents mean fold changes. The Y-axis has been set to 1 to
normalize the graph to the control.
Table 9: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight
culture on the expression of SREBP-1c in 3T3-L1A adipocytes
Relative expressiona

FSB concentration (µl/ml media)
0µl/ml

1

10µl/ml

0.99

25µl/ml

1.284

50µl/ml

1.442

75µl/ml

1.225

100µl/ml

1.07

a

Expression values are mean fold changes. n = 7 to 15. Mean fold changes are of protein

expression relative to the positive control.
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Figure 12a
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Figure12: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture
on the expression of SREBP-1c in 3T3-L1A adipocytes. Figure 12a is the western blot
image. Figure 12b represents the quantification of the protein expression. Expression
is presented as fold change relative to the control CE concentration of 0µl/ml. Each bar
represents mean fold changes. The Y-axis has been set to 1 to normalize the graph to
the control.
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Table 10: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture
on the expression of SREBP-1c in 3T3-L1A adipocytes
CE concentration (µl/ml media)

Relative expressiona

0µl/ml

1

10µl/ml

1.155

25µl/ml

1.183

50µl/ml

0.975

75µl/ml

1.291

100µl/ml

1.344

a

Expression values are mean fold changes. n = 1 to 7. Mean fold changes are of protein

expression relative to the positive control.

Comparing PPAR³ Agonistic Ability of Probiotic Extract with Rosiglitazone
The initial Western Blot data suggested that PPAR³ , and to a lesser degree
C/EBP±, were upregulated by FSB treatment. The next step was to compare the
agonistic ability of FSB treatment to a known PPAR agonist, rosiglitazone.
Rosiglitazone was being used as a part of the cell culture differentiation treatment to
produce high differentiation rates. For this part of the study, rosiglitazone was excluded
from media of cells being treated with FSB, thus allowing the comparison of adipogenic
protein expression in cells treated with FSB and cells treated with a thiazolidinedione.
Table 11 shows the results of the Western blot.
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Figure 13
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Figure 13. Western blot image of comparative FSB and rosiglitazone treatments.
Treatment numbering is as follows: 1 = 0 FSB/No Rosiglitazone, 2 = 0
FSB/Rosiglitazone, 3 = 50 FSB/No Rosiglitazone, 4 = 100 FSB/No Rosiglitazone.
Table 11: Comparison of PPAR³ Expression levels from FSB treatment and
Rosiglitazone

Treatment

PPARγ Expression

0 FSB/No Rosiglitazone

1

0 FSB/Rosiglitazone

1.75

50 FSB/No Rosiglitazone

2.01

100 FSB/No Rosiglitazone

2.04

Western blot analysis revealed the possible PPAR³ agonistic quality of FSB. FSB
produced similar enhanced PPAR³ expression as Rosiglitazone, a known PPAR³
agonist.
Analysis of the cell culture treated with FSB without Rosiglitazone showed that
the FSB treatment increased PPAR expression levels from control cells without
Rosiglitazone. The analysis also showed that FSB treatment was able to upregulate
PPAR expression to levels comparable to cells treated with Rosiglitazone. This
indicates that the FSB treatment has comparable PPAR agonistic qualities to that of
known PPAR agonists.
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Testing Heat Inactivated Broth for Adipogenic Potential
To examine the possibility that the FSB contained a heat labile biomolecule, the
FSB was boiled to denature any possible secreted proteins and then used as a cell
culture treatment. Western blot analysis of PPAR³ and ATGL expression showed that
heat inactivated the active component in the FSB treatment. Expression levels for both
proteins were reduced to levels below control treatment (Tables 11 and 12).

Ppar³ 2
Ppar³ 1

Figure 14a

14b

ATGL
0

10

25

50

75

100 µl/ml FSB

Figure 14a. Western blot image of PPAR³ 1 and 2 after HIB treatment.
14b. Western blot image of ATGL after HIB treatment.
Table 12: Effect of heat inactivated broth (HIB) on Expression of PPAR³ 1, PPAR³ 2,
and ATGL
Treatment

³ 1 Expression

³ 2 Expression

ATGL Expression

0µl/ml

1

1

1

10µl/ml

-1.96

-1.68

-1.53

25µl/ml

-3.02

-2.92

-1.46

50µl/ml

-3.38

-2.06

-1.4

75µl/ml

-1.15

-1.52

-1.93

100µl/ml
-2.42
-2.06
-3.11
Table 12 shows the results of PPAR³ Western blot analysis on HIB treated cell culture.
Expression levels for both ³ 1 and ³ 2 under HIB treatment were reduced from observed
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values for FSB treatment. Expression of ATGL under HIB treatment was reduced from
the observed values for FSB treatment.

Oil-Red-O Staining and Quantification of Lipid Content
An Oil Red O test was performed to measure the lipid content of each well. The
data collected indicates that there was a slight rise in lipid content with the 10 and
25µl/ml FSB treatment. A gradual drop in lipid content was observed after 50µl/ml FSB
treatment. Cell death due to FSB treatment over 25µl/ml FSB treatment was observed
with this experiment. Lower cell density could contribute to the lower than expected
lipid content of the cells.
1.6

OD at 500nm

1.4
1.2
1
0.8
0.6
0.4
0.2
0
0μl/ml

10μl/ml

25μl/ml

50μl/ml

75μl/ml

100μl/ml

FSB treatment

Figure 15: Oil-Red-O (ORO) staining and quantification by spectrophotometry of lipid
content of mature 3T3-L1A cells treated with filtered spent broth (FSB) from a
Lactobacillus rhamnosus overnight culture. Optical Density (OD) readings were taken
at 500nm.
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Table 13: Oil-Red-O (ORO) staining and quantification by spectrophotometry of lipid
content of mature 3T3-L1A cells treated with filtered spent broth (FSB) from a
Lactobacillus rhamnosus overnight culture

FSB concentration (µl/ml media) Optical Density Measured at 500nm
0µl/ml
1.16
10µl/ml
1.41
25µl/ml
1.41
50µl/ml
1.03
75µl/ml
0.9
100µl/ml
0.64
ORO lipid content per well for FSB treatment of Cell culture. The optical density
measurements were taken via spectrophotometry set to 500nm.

Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus Overnight Culture
in Enterocytes
FSB was used to treat Caco-2 cell culture to measure differences in protein
expression for transcription factors important in lipid transport. Western blot analysis of
SREBP-1c indicated that the FSB treatment did not affect protein expression (Table 14,
Figure 16). MTTP protein showed an increased expression of 1.2 fold during the 100
µl/ml FSB treatment (Table 15, Figure 17).
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Figure 16: Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus
overnight culture on the expression of SREBP-1c in Caco-2 cells. Figure 16a is the
western blot image. Figure 16b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of 0
µl/ml. Each bar represents mean fold changes. The Y-axis has been set to 1 to
normalize the graph to the control.
Table 14: Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus
overnight culture on the expression of SREBP-1c in Caco-2 cells
Relative expressiona
1
0.935
1.086
1.117
1.063
0.929

FSB concentration (µl/ml media)
0µl/ml
10µl/ml
25µl/ml
50µl/ml
75µl/ml
100µl/ml
a

Expression values are mean fold changes. n = 4. Mean fold changes are of protein

expression relative to the positive control.
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Figure 17a
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Figure 17: Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus
overnight culture on the expression of MTTP in Caco-2 cells. Figure 17a is the western
blot image. Figure 17b represents the quantification of the protein expression.
Expression is presented as fold change relative to the control FSB concentration of 0
µl/ml. Each bar represents mean +/- standard deviation. The Y-axis has been set to 1
to normalize the graph to the control.
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Table 15: Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus
overnight culture on the expression of MTTP in Caco-2 cells
Relative expressiona

FSB concentration (µl/ml media)
0µl/ml

1

10µl/ml

0.943

25µl/ml

1.151

50µl/ml

1.073

75µl/ml

1.065

100µl/ml

1.224

a

Expression values are mean fold changes. n = 2. Mean fold changes are of protein

expression relative to the positive control.
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CHAPTER 4
DISCUSSION
With the obesity epidemic rising, more needs to be understood about the
disease and possible new treatments. This study was performed to gain possible
insight into the therapeutic uses of probiotics. The study tested a novel probiotic
against a cell culture model of adipogenesis. Protein expression changes attributed to
probiotic treatment of the cells. Western blot analysis showed that filtered spent broth
(FSB) treatment upregulated key adipogenic transcription factors, PPAR³ , C/EBP±, and
ATGL expression. Contrasting findings have been reported where the adipogenic
transcription factors were downregulated by probiotic treatment. Other probiotic antiobesity studies have given contradictory findings to what was observed in the present
study. Moon et al. (2012) showed that cytoplasmic fraction and cell free cultured
medium of Weisella koreensis lowered lipid accumulation and mRNA expression of key
transcription factors in differentiating adipocyte cell culture. Another study used cell
extract of Lactobacillus brevis OPK-3 to downregulate expression of PPAR³ and
C/EBP± (Park et al. 2014). By comparing the findings of this study to previously
reported findings, it becomes clearer that different probiotics elicit strain specific
responses.

Once the Western blot analysis indicated that there could be PPAR³ agonistic
qualities associated with the FSB treatment, the next step was to test the FSB treatment
against known PPAR³ agonists. Since rosiglitazone was already being used to produce
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high differentiation in the cell culture, it was chosen for the PPAR³ agonist. The results
indicated that FSB treatment was able to upregulate PPAR³ to levels comparable to
rosiglitazone. The factor in FSB was inactivated by heat and is likely to be a heat labile
protein or biomolecule. This is important in the search for new anti-diabetic drugs.
Rosiglitazone is a potent drug against insulin resistance associated with Type 2
Diabetes (Gerstein et al. 2006). The drawback is that this drug can cause severe side
effects. It is possible that the compound in the FSB treatment could be used to replace
rosiglitazone, or a probiotic regimen could be used in conjunction with rosiglitazone to
improve effectiveness while lowering drug dosage.
The gastrointestinal lumen stands as the physical barrier between the body and
the gut microbiota. Studies by Kim (Kim et al. 2013) and Marcil (Marcil et al. 2003) have
shown that the microbiome and biomolecules are able to interact with the gastric lumen
to alter protein expression. This interaction is not well understood, but it could have an
impact on how lipids are transported and stored. In the present study, FSB did not
affect the expression of proteins SREBP-1c and MTTP that are known to play important
roles in lipid transport. However, some probiotics have been shown to elicit strain
specific responses of the gastrointestinal epithelial cells. In the study by Putaala et al.
(2010), cell to cell adhesion, superoxide metabolism, and MAPK pathway were all
regulated differently by the various probiotic bacteria.
The Oil-Red-O (ORO) staining in the present study showed that lipid content rose
with the 10 and 25 µl/ml and then dropped with higher FSB doses. 50 µl/ml and above
FSB treatments were observed to cause cell death during the ORO study. One
drawback with ORO is that it only measures the amount of lipid content in each well
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instead of measuring lipid content within each cell. Since there was cell death involved
with some batches of the FSB treatment, this could have led to lower total lipid content
readings.
An interesting observation during this study was that certain FSB treatments
seemed to cause increased cell culture detachment and death. This was not observed
with the first batch of FSB treatment made, but in some subsequent batches cell death
was observed. Fresh MRS broth treatment was explored as a possible control
treatment for FSB, but it was determined that MRS caused high cell death among the
cells being cultured. It is possible that during some of the FSB preparations, the
spectrophotometer that was used to measure optical density (OD) reading was not set
to the same wavelength as previous batches. This could have given a premature
reading of 2.0 OD leading to shortened growth times for some FSB treatments. Fresh
MRS broth and FSB that had a shortened bacterial growth time seemed to produce high
cell death when used as cell culture treatment. This observation led to the examination
of the ingredients that make up MRS broth. When looking at the ingredients listed in
MRS broth, one ingredient stood out as being a possible culprit for the cell death.
Sodium acetate is included in MRS broth as both an energy source to the bacteria and
a selective agent to prevent certain other organisms from growing in the broth. Sodium
acetate has been shown to have cytotoxic effects in high doses (Sun et al. 2005).
Normally the L. rhamnosus isolate would use up the sodium acetate as an energy
source, but due to shorter incubation times for some of the FSB treatment batches, the
bacteria did not have the time to break down the sodium acetate present in the broth.
This could explain the decrease in cell viability associated with some of the FSB
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batches with shorter bacterial incubation periods, as well as explain the high cytotoxicity
of fresh MRS broth. It would be beneficial to mix an MRS broth without sodium acetate
to see if the probiotic bacteria will grow, and if the broth causes high cell culture death.
Cell death caused by possible sodium acetate cytotoxicity could explain
irregularities in the Oil-Red-O (ORO) results. Quantification of ORO actually measures
lipid content per cell culture well instead of lipid content per cell culture cell. As the FSB
treatment levels increased higher cell death was observed. This means that the 75 and
100µl/ml treatments induced higher cell death than the control. The resultant difference
in cell numbers would mean that the high treatment wells had lower density of cells
contributing to lower lipid content readings. Another possibility is that the cells were
stressed by the cytotoxic compound. This stress could have hampered the adipocyte’s
ability to store lipids. The higher FSB treatments would have put higher stress on the
cells, thereby giving the effect of lower lipid content with higher FSB treatment.
A recent study showed that Lactobacillus rhamnosus secretes proteins into
surrounding media as the bacteria grows (Sanchez et al. 2009). The protein expression
changes caused by FSB treatment with no changes seen from the CE treatment
suggest that this isolate secretes a possible biomolecule into the surrounding
environment that are cause these changes. Inactivation of the FSB by heat suggests
that this biomolecule is heat labile. The source that was used to isolate the potential
probiotic tested in this study was by all accounts, novel, and this specific L. rhamnosus
strain could have peculiar characteristics, perhaps contradictory to other previously
isolated strains.
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At first thought, the idea of reducing adipogenesis may seem like the correct way
to battle the continuing obesity epidemic. The problem with this idea is that obesity is
considered a state of energy excess, whereby caloric intake is higher than energy
expenditure. If adipogenesis is reduced without fixing the energy imbalance then the
excess glucose and fatty acids will continue to build in the blood and be forced to be
stored in the liver and other tissues. This can cause hepatomegaly, fatty liver disease,
hyperlipidemia and other diseases characterized by increased circulating or improperly
stored lipids (Rosen et al. 2000). The more appropriate approach is to increase
adipogenesis to allow for proper clearance of circulating lipids, while at the same time
addressing the energy imbalance. This study was designed to test the ability of a novel
probiotic milk isolate L. rhamnosus to influence adipogenesis in vitro. Indeed,
biomolecules present in spent culture from this isolate were able to increase
adipogenesis when administered to differentiating adipocytes.
In summary, an overnight filtered spent broth (FSB) culture of a Lactobacillus
rhamnosus isolate from “amabere amaruranu”, Kenyan traditional cultured milk
preparation upregulated , PPAR³ , C/EBP±, and ATGL adipogenic transcription factors.
The active ingredient in the FSB seemed to be heat-labile in nature. Finally, because
the FSB shared similar PPAR³ agonistic ability as rosiglitazone, a diabetic drug, there
might be a possibility of use of this biomolecule in development of new therapies.
Future research to define the limits and potential of any treatment with this
probiotic needs to be conducted. The biomolecule that causes the observed changes in
protein expression level and differentiation needs to be isolated and identified. This
biomolecule could be very important in finding novel treatments for type 2 diabetes by
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its potential to upregulate PPAR³ similar to current treatments. The probiotic itself
should be tested in an animal model of obesity to further investigate the efficacy of a
probiotic approach to obesity treatment. If able to be isolated, the biomolecule will have
to go through cell culture testing to show that this compound causes the same effects
as observed in this study, proving that it is the active agent in the FSB treatment shown
in the present study.

62

REFERENCES

Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. 2004. Probiotics for treating
infectious diarrhoea. Cochrane Database Syst Rev. (2):CD003048.
Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD,
Jakobsen M, Pedersen BK. 2010. Effects of lactobacillus acidophilus ncfm on
insulin sensitivity and the systemic inflammatory response in human subjects.
The British journal of nutrition. 104(12):1831-1838.
Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. 2000. Insulin
effects on sterol regulatory-element-binding protein-1c (srebp-1c) transcriptional
activity in rat hepatocytes. Biochem J. 350 Pt 2:389-393.
Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon
JI. 2004. The gut microbiota as an environmental factor that regulates fat
storage. Proceedings of the National Academy of Sciences of the United States
of America. 101(44):15718-15723.
Bager P, Wohlfahrt J, Westergaard T. 2008. Caesarean delivery and risk of atopy and
allergic disease: Meta-analyses. Clin Exp Allergy. 38(4):634-642.
Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. 2011. Exposure to a
social stressor alters the structure of the intestinal microbiota: Implications for
stressor-induced immunomodulation. Brain, behavior, and immunity. 25(3):397407.
Bergman EN. 1990. Energy contributions of volatile fatty acids from the gastrointestinal
tract in various species.
63

Boyiri B, Kotala J, Lampson B, Onyango E. 2014. Cultured milk bacterial isolates
survive well in digestive tract conditions and could be potential probiotic
candidates. Faseb Journal. 28(1).
Chakrabarti P, Kandror KV. 2011. Adipose triglyceride lipase: A new target in the
regulation of lipolysis by insulin. Current Diabetes Review. 7(1875-6417
(Electronic)):270-277.
Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. 2009. Specific duodenal
and faecal bacterial groups associated with paediatric coeliac disease. Journal of
clinical pathology. 62(3):264-269.
Das A, Mukhopadhyay S. 2011. The evil axis of obesity, inflammation and type-2
diabetes. Endocrine, metabolic & immune disorders drug targets. 11(1):23-31.
Dash S, Xiao C, Morgantini C, Lewis GF. 2015. New insights into the regulation of
chylomicron production. Annu Rev Nutr. 35:265-294.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV,
Devlin AS, Varma Y, Fischbach MA et al. 2014. Diet rapidly and reproducibly
alters the human gut microbiome. Nature. 505(7484):559-563.
De Palma G, Collins SM, Bercik P, Verdu EF. 2014. The microbiota-gut-brain axis in
gastrointestinal disorders: Stressed bugs, stressed brain or both? The Journal of
physiology. 592(Pt 14):2989-2997.
Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight
R. 2010. Delivery mode shapes the acquisition and structure of the initial
microbiota across multiple body habitats in newborns. Proceedings of the

64

National Academy of Sciences of the United States of America. 107(26):1197111975.
Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR,
Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora.
Science. 308(5728):1635-1638.
Farmer SR. 2006. Transcriptional control of adipocyte formation. Cell metabolism.
4(4):263-273.
Finegold SM. 2011. State of the art; microbiology in health and disease. Intestinal
bacterial flora in autism. Anaerobe. 17(6):367-368.
Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E,
Summanen PH, Granpeesheh D, Dixon D et al. 2010. Pyrosequencing study of
fecal microflora of autistic and control children. Anaerobe. 16(4):444-453.
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M,
Hoogwerf B, Laakso M, Mohan V et al. 2006. Effect of rosiglitazone on the
frequency of diabetes in patients with impaired glucose tolerance or impaired
fasting glucose: A randomised controlled trial. Lancet. 368(9541):1096-1105.
Geurts L, Everard A, Van Hul M, Essaghir A, Duparc T, Matamoros S, Plovier H, Castel
J, Denis RG, Bergiers M et al. 2015. Adipose tissue nape-pld controls fat mass
development by altering the browning process and gut microbiota. Nat Commun.
6:6495.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint
HJ, Salminen S et al. 2013. Expert consensus document: The international

65

scientific association for probiotics and prebiotics consensus statement on the
scope and appropriate use of the term probiotic. (1759-5053 (Electronic)).
Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, Park SY, Yoon HS, Cho GS, Franz
CM et al. 2012. Modulation of the murine microbiome with a concomitant antiobesity effect by lactobacillus rhamnosus gg and lactobacillus sakei nr28.
Beneficial microbes. 3(1):13-22.
Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima
M, Tsuchida T. 2010. Regulation of abdominal adiposity by probiotics
(lactobacillus gasseri sbt2055) in adults with obese tendencies in a randomized
controlled trial. European journal of clinical nutrition. 64(6):636-643.
Kajander K, Myllyluoma E, Rajilic-Stojanovic M, Kyronpalo S, Rasmussen M, Jarvenpaa
S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. 2008. Clinical trial:
Multispecies probiotic supplementation alleviates the symptoms of irritable bowel
syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 27(1):4857.
Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO. 2013. Anti-obesity effect of
lactobacillus gasseri bnr17 in high-sucrose diet-induced obese mice. PloS one.
8(1):e54617.
Kim B, Park Y, Wegner CJ, Bolling BW, Lee J. 2013. Polyphenol-rich black chokeberry
(aronia melanocarpa) extract regulates the expression of genes critical for
intestinal cholesterol flux in caco-2 cells. The Journal of nutritional biochemistry.
24(9):1564-1570.

66

Kim JY, Tillison K, Lee JH, Rearick DA, Smas CM. 2006. The adipose tissue triglyceride
lipase atgl/pnpla2 is downregulated by insulin and tnf-alpha in 3t3-l1 adipocytes
and is a target for transactivation by ppargamma. American journal of physiology
Endocrinology and metabolism. 291(1):E115-127.
Lass A, Zimmermann R, Oberer M, Zechner R. 2011. Lipolysis - a highly regulated
multi-enzyme complex mediates the catabolism of cellular fat stores. Progress in
lipid research. 50(1):14-27.
Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH.
2006. Human originated bacteria, lactobacillus rhamnosus pl60, produce
conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice.
Biochimica et biophysica acta. 1761(7):736-744.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995.
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome
proliferator-activated receptor gamma (ppar gamma). The Journal of biological
chemistry. 270(22):12953-12956.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity
alters gut microbial ecology. Proceedings of the National Academy of Sciences of
the United States of America. 102(31):11070-11075.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. 2006. Microbial ecology: Human gut
microbes associated with obesity. Nature. 444(7122):1022-1023.
Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished
hepatic response to fasting/refeeding and liver x receptor agonists in mice with

67

selective deficiency of sterol regulatory element-binding protein-1c. The Journal
of biological chemistry. 277(11):9520-9528.
Liou AP, Paziuk M, Luevano JM, Jr., Machineni S, Turnbaugh PJ, Kaplan LM. 2013.
Conserved shifts in the gut microbiota due to gastric bypass reduce host weight
and adiposity. Science translational medicine. 5(178):178ra141.
Majamaa H, Isolauri E. 1997. Probiotics: A novel approach in the management of food
allergy. J Allergy Clin Immunol. 99(2):179-185.
Marcil V, Delvin E, Garofalo C, Levy E. 2003. Butyrate impairs lipid transport by
inhibiting microsomal triglyceride transfer protein in caco-2 cells. J Nutr.
133(7):2180-2183.
Maynard CL, Elson CO, Hatton RD, Weaver CT. 2012. Reciprocal interactions of the
intestinal microbiota and immune system. Nature. 489(7415):231-241.
Moon YJ, Soh JR, Yu JJ, Sohn HS, Cha YS, Oh SH. 2012. Intracellular lipid
accumulation inhibitory effect of weissella koreensis ok1-6 isolated from kimchi
on differentiating adipocyte. Journal of applied microbiology. 113(3):652-658.
Nauli AM, Nauli SM. 2013. Intestinal transport as a potential determinant of drug
bioavailability. Curr Clin Pharmacol. 8(3):247-255.
Nistal E, Caminero A, Vivas S, Ruiz de Morales JM, Saenz de Miera LE, RodriguezAparicio LB, Casqueiro J. 2012. Differences in faecal bacteria populations and
faecal bacteria metabolism in healthy adults and celiac disease patients.
Biochimie. 94(8):1724-1729.

68

O'Toole PW, Cooney JC. 2008. Probiotic bacteria influence the composition and
function of the intestinal microbiota. Interdisciplinary perspectives on infectious
diseases. 2008:175285.
Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. 2007. Development of the
human infant intestinal microbiota. PLoS biology. 5(7):e177.
Pan X, Hussain MM. 2012. Gut triglyceride production. Biochimica et biophysica acta.
1821(5):727-735.
Park DY, Ahn YT, Huh CS, Jeon SM, Choi MS. 2011. The inhibitory effect of
lactobacillus plantarum ky1032 cell extract on the adipogenesis of 3t3-l1 cells.
Journal of medicinal food. 14(6):670-675.
Park JE, Oh SH, Cha YS. 2014. Lactobacillus brevis opk-3 isolated from kimchi inhibits
adipogenesis and exerts anti-inflammation in 3t3-l1 adipocyte. Journal of the
science of food and agriculture. 94(12):2514-2520.
Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, Pestel J, Mercenier A. 2002.
Lactic acid bacteria inhibit th2 cytokine production by mononuclear cells from
allergic patients. J Allergy Clin Immunol. 110(4):617-623.
Putaala H, Barrangou R, Leyer GJ, Ouwehand AC, Hansen EB, Romero DA, Rautonen
N. 2010. Analysis of the human intestinal epithelial cell transcriptional response
to lactobacillus acidophilus, lactobacillus salivarius, bifidobacterium lactis and
escherichia coli. Beneficial microbes. 1(3):283-295.
Qiao L, Zou C, Shao P, Schaack J, Johnson PF, Shao J. 2008. Transcriptional
regulation of fatty acid translocase/cd36 expression by ccaat/enhancer-binding
protein alpha. The Journal of biological chemistry. 283(14):8788-8795.

69

Rajilic-Stojanovic M, Smidt H, de Vos WM. 2007. Diversity of the human gastrointestinal
tract microbiota revisited. Environmental microbiology. 9(9):2125-2136.
Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. 2002. Ppargamma
knockdown by engineered transcription factors: Exogenous ppargamma2 but not
ppargamma1 reactivates adipogenesis. Genes Dev. 16(1):27-32.
Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V,
Henrissat B, Bain JR et al. 2013. Gut microbiota from twins discordant for obesity
modulate metabolism in mice. Science. 341(6150):1241214.
Rosen ED, Sarraf P Fau - Troy AE, Troy Ae Fau - Bradwin G, Bradwin G Fau - Moore
K, Moore K Fau - Milstone DS, Milstone Ds Fau - Spiegelman BM, Spiegelman
Bm Fau - Mortensen RM, Mortensen RM. 1999. Ppar gamma is required for the
differentiation of adipose tissue in vivo and in vitro. (1097-2765 (Print)).
Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. 2000. Transcriptional regulation
of adipogenesis. Genes Dev. 14(11):1293-1307.
Samuel BS, Gordon JI. 2006. A humanized gnotobiotic mouse model of host-archaealbacterial mutualism. Proceedings of the National Academy of Sciences of the
United States of America. 103(26):10011-10016.
Sanchez B, Schmitter JM, Urdaci MC. 2009. Identification of novel proteins secreted by
lactobacillus rhamnosus gg grown in de mann-rogosa-sharpe broth. Lett Appl
Microbiol. 48(5):618-622.
Sanders ME. 2008. Probiotics: Definition, sources, selection, and uses. Clinical
infectious diseases : an official publication of the Infectious Diseases Society of
America. 46 Suppl 2:S58-61; discussion S144-151.

70

Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. 1997. Differential
expression of exons 1a and 1c in mrnas for sterol regulatory element binding
protein-1 in human and mouse organs and cultured cells. The Journal of clinical
investigation. 99(5):838-845.
Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, Tjota MY, Seo GY,
Cao S, Theriault BR et al. 2014. Commensal bacteria protect against food
allergen sensitization. Proceedings of the National Academy of Sciences of the
United States of America. 111(36):13145-13150.
Sun J, Bi L, Chi Y, Aoki K, Misumi J. 2005. Effect of sodium acetate on cell proliferation
and induction of proinflammatory cytokines: A preliminary evaluation. Food Chem
Toxicol. 43(12):1773-1780.
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. 1994a. Mppar gamma 2:
Tissue-specific regulator of an adipocyte enhancer. Genes & Development.
8(10):1224-1234.
Tontonoz P, Hu E, Spiegelman BM. 1994b. Stimulation of adipogenesis in fibroblasts by
ppar gamma 2, a lipid-activated transcription factor. Cell. 79(7):1147-1156.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An
obesity-associated gut microbiome with increased capacity for energy harvest.
Nature. 444(7122):1027-1031.
Victor DW, 3rd, Quigley EM. 2014. Hepatic encephalopathy involves interactions among
the microbiota, gut, brain. Clin Gastroenterol Hepatol. 12(6):1009-1011.
Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ,
Spiegelman BM. 1999. Cross-regulation of c/ebp alpha and ppar gamma controls

71

the transcriptional pathway of adipogenesis and insulin sensitivity. Molecular cell.
3(2):151-158.
Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. 2009. Adipose
triglyceride lipase and the lipolytic catabolism of cellular fat stores. Journal of lipid
research. 50(1):3-21.
Zechner R, Strauss JG, Haemmerle G, Lass A, Zimmermann R. 2005. Lipolysis:
Pathway under construction. Current opinion in lipidology. 16(3):333-340.
Zeissig S, Blumberg RS. 2014. Life at the beginning: Perturbation of the microbiota by
antibiotics in early life and its role in health and disease. Nat Immunol. 15(4):307310.
Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R,
Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A et al. 2004. Fat
mobilization in adipose tissue is promoted by adipose triglyceride lipase.
Science. 306(5700):1383-1386.
Zuo Y, Qiang L, Farmer SR. 2006. Activation of ccaat/enhancer-binding protein (c/ebp)
alpha expression by c/ebp beta during adipogenesis requires a peroxisome
proliferator-activated receptor-gamma-associated repression of hdac1 at the
c/ebp alpha gene promoter. The Journal of biological chemistry. 281(12):79607967.

72

VITA
JUSTIN KOTALA

Education:

B.S. in Biomedical Sciences, University of South Florida,
Tampa, FL 2011
M.S. in Biology, East Tennessee State University,
Johnson City, TN 2015

Professional Experience:

Graduate Assistant, East Tennessee State University,
College of Public Health, 2013—2015

Publications:

Adipogenesis May Be Influenced By Lactobacillus
Cultured Milk Isolate, Poster Presentation at
Appalachian Research Forum, Johnson City, TN,
2015
Lactobacillus rhamnosus Cultured Milk Isolate May
Reduce Adipogenesis, Poster Presentation at
Experimental Biology Conference, Boston, MA,
2015
Influence of Lactobacillus rhamnosus isolated from
“amabere amaruranu”, Oral presentation at East
Tennessee State University, Johnson City, TN,
2014

73

